Christopher Ryan Sullivan Sells 8,458 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 8,458 shares of the stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $13.09, for a total transaction of $110,715.22. Following the completion of the transaction, the chief financial officer owned 8,880 shares of the company’s stock, valued at $116,239.20. This represents a 48.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, April 30th, Christopher Ryan Sullivan sold 8,457 shares of Avalo Therapeutics stock. The stock was sold at an average price of $13.23, for a total transaction of $111,886.11.
• On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00.
• On Wednesday, April 1st, Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock. The stock was sold at an average price of $16.77, for a total transaction of $133,807.83.

Avalo Therapeutics Stock Up 2.3%

Shares of NASDAQ:AVTX traded up $0.31 during trading on Friday, reaching $13.71. The stock had a trading volume of 720,705 shares, compared to its average volume of 613,175. The stock has a market cap of $366.25 million, a P/E ratio of -2.39 and a beta of 0.93. The business has a fifty day moving average price of $15.29 and a 200-day moving average price of $16.19. Avalo Therapeutics, Inc. has a fifty-two week low of $3.39 and a fifty-two week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to analysts’ expectations of ($0.21) million. As a group, equities analysts forecast that Avalo Therapeutics, Inc. will post -4.04 EPS for the current year.

Institutional Investors Weigh In On Avalo Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caligan Partners LP purchased a new position in shares of Avalo Therapeutics in the 3rd quarter worth about $10,592,000. Balyasny Asset Management L.P. purchased a new stake in shares of Avalo Therapeutics during the 3rd quarter worth about $10,390,000. Vanguard Group Inc. grew its holdings in shares of Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after purchasing an additional 525,696 shares during the period. Millennium Management LLC increased its position in Avalo Therapeutics by 380.2% during the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after purchasing an additional 522,548 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in Avalo Therapeutics during the 4th quarter worth approximately $8,637,000. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AVTX. BTIG Research reiterated a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research note on Monday, April 13th. HC Wainwright lifted their price target on Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Citizens Jmp began coverage on shares of Avalo Therapeutics in a report on Monday, April 6th. They set an “outperform” rating and a $52.00 price objective on the stock. Wolfe Research initiated coverage on shares of Avalo Therapeutics in a research report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Wednesday, April 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Avalo Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $44.83.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.